The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report.
The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report.
复制标题
酒精生物标志物磷脂酰乙醇在治疗住院患者疑似酒精戒断方面的可能临床效用:病例报告。
DOI:
10.1111/ajad.13516
复制
发表时间:
2024
期刊:
影响因子:
--
通讯作者:
Suzuki,Joji
中科院分区:
文献类型:
--
作者:
Edinoff,AmberN;Hathaway,DavidB;MartinezGarza,David;Rosen,JordanH;Suzuki,Joji
Background and ObjectivesThe decision to initiate pharmacotherapy for alcohol withdrawal is typically based on examining self‐reported use of alcohol and symptoms of withdrawal. Phosphatidylethanol (PEth) is a biomarker that could aim in clinical decision‐making in withdrawal management.MethodsThis report describes three cases highlighting the potential clinical utility of PEth in caring for individuals at risk for alcohol withdrawal.ResultsTwo of the cases received phenobarbital when their PEth showed that the risk of withdrawal was low and one case where PEth could have shown this was needed. The results were only available in a delayed fashion, however, could have been useful in informing clinical care.Discussion and ConclusionPEth can be a useful tool if available without delay. PEth can be used to quickly rule out alcohol withdrawal and avoid misdiagnoses and prolonged hospital stays.Scientific SignificanceThis is a clinical case study available looking at PEth and withdrawal in hospitalized patients. It proposes that PEth can be used as a way to quickly rule out alcohol withdrawal to avoid misdiagnoses and the possibility of a prolonged hospital stay.